AC
PASG icon

Annandale Capital’s Passage Bio PASG Stock Holding History

Annandale Capital’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,717
Closed -$51K – 142
2023
Q2 		$51K Hold
2,717
– – 0.01% 134
2023
Q1 		$52K Hold
2,717
– – 0.02% 130
2022
Q4 		$75K Buy
2,717
+717
+36% +$18.1K 0.02% 127
2022
Q3 		$50K Buy
+2,000
New +$78.8K 0.02% 129

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Annandale Capital's PASG Position: Q3 2023 in Review

Annandale Capital sold out of Passage Bio (PASG) in Q3 2023, closing a stake of 2,717 shares — an estimated $51K sold.

Annandale Capital first reported a position in PASG in Q3 2022 and held it in 4 quarters. The position peaked at $75K in Q4 2022. 48 funds tracked by Wall St. Rank hold PASG as of Q3 2023.

  • Annandale Capital reported no remaining Passage Bio position as of Q3 2023 after selling out during the quarter.
  • Annandale Capital sold 2,717 Passage Bio shares in Q3 2023, an estimated $51K.
  • Annandale Capital first reported a position in Passage Bio in Q3 2022 and held it in 4 quarters.
  • Annandale Capital's Passage Bio position peaked at $75K in Q4 2022.
  • 48 funds tracked by Wall St. Rank held Passage Bio as of Q3 2023.

Based on Annandale Capital's 13F filing for Q3 2023, filed 15 Nov 2023.